- Ensure the correct functioning of the site
- Provide you the best service
- Enhance your user experience
- Optimize our website
Learn more in cookies statement & settings
Prof. François Goldwasser
Presentation Roadmap/ Summary
An increasing number of patients have not only cancer but also other characteristics susceptible to influence the tolerability to anticancer treatments: elderly, obesity, cardiovascular disease, mellitus diabetes, malnutrition. As a result, a view of the cancer patient limited to the consultation of the oncologist may miss risks of toxicity. Conversely, the oncologist may also overestimate the risk and renounce to a feasible treatment. A step of multidisciplinary needs and risks assessment improves the quality of the prescription and reduces the anticancer treatment-related unscheduled hospitalizations.
At the conclusion of the presentation, the participant will be able to:
Key Takeaways/ Fast Facts
Using this link will let you leave a website of Fresenius Kabi Deutschland GmbH (“Fresenius Kabi”) or to a different domain under the control of Fresenius Kabi. In the event that the linked site is not under the control of Fresenius Kabi but under the control of a third party or an affiliate in the Fresenius group of companies, Fresenius Kabi shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Fresenius Kabi of the site.
Do you want to continue?